Showing results (321-330 of 399) with videos related to

Sort By:
Pageof 40
Contemporary Clinical Trials|April 14, 2015
Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) modelAnjali Gupta, Karen J Calfas, Simon J Marshall, et al.
Blood Advances|January 11, 2022
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphomaLoretta J Nastoupil, Collin K Chin, Jason R Westin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2021
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell LymphomaPier Luigi Zinzani, Thomas Rodgers, Dario Marino, et al.
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
British Journal of Haematology|September 9, 2004
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantationMichael R Bishop, Seth M Steinberg, Ronald E Gress, et al.
Contemporary Clinical Trials|November 13, 2013
Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART)K Patrick, S J Marshall, E P Davila, et al.
Bone Marrow Transplantation|July 10, 2012
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patientsM Foglietta, S S Neelapu, L W Kwak, et al.
Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.
British Journal of Haematology|March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized StudyLoretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
Pageof 40